
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is well-positioned for success with the upcoming launch of its presbyopia eye drop, VIZZ, which is powered by a novel and differentiated mechanism of action. With an experienced sales team and a DTC campaign featuring Sarah Jessica Parker, the company is expected to see a gradual increase in sales over the next several quarters. While there are risks to the investment thesis, we maintain a Buy rating with a target price of $38, based on our conservative estimates and in line with industry standards.
Bears say
LENZ Therapeutics is facing several challenges in the near term, including a competitive presbyopia market and the need to validate VIZZ's commercial success. Additionally, the company faces risks such as failure to secure funding and reach peak revenue estimates, which could affect their ability to continue program development and commercialization. As a result, the negative outlook is based on concerns about the company's ability to establish widespread adoption of VIZZ and sustain long-term growth.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares